Regeneron Pharma (REGN) PT Raised to $382 at Roth Capital
Tweet Send to a Friend
Roth Capital maintained a Buy rating on Regeneron Pharma (NASDAQ: REGN) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


